Washington Trust Advisors, Inc. Cassava Sciences Inc Transaction History
Washington Trust Advisors, Inc.
- $1.06 Billion
- Q2 2024
A detailed history of Washington Trust Advisors, Inc. transactions in Cassava Sciences Inc stock. As of the latest transaction made, Washington Trust Advisors, Inc. holds 75 shares of SAVA stock, worth $2,056. This represents 0.0% of its overall portfolio holdings.
Number of Shares
75
Previous 75
-0.0%
Holding current value
$2,056
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SAVA
# of Institutions
185Shares Held
13.3MCall Options Held
1.38MPut Options Held
2.04M-
Black Rock Inc. New York, NY3.22MShares$88.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.68MShares$73.6 Million0.0% of portfolio
-
State Street Corp Boston, MA1.18MShares$32.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA967KShares$26.5 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA691KShares$18.9 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $1.1B
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...